JAK inhibition: the key to treating myeloproliferative neoplasm?

Expert Rev Hematol. 2012 Dec;5(6):583-5. doi: 10.1586/ehm.12.55.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Bone Marrow Neoplasms / drug therapy*
  • Bone Marrow Neoplasms / enzymology
  • Bone Marrow Neoplasms / genetics
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors*
  • Janus Kinase 2 / genetics
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / enzymology
  • Myeloproliferative Disorders / genetics
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use
  • Quality of Life

Substances

  • INCB018424
  • Protein Kinase Inhibitors
  • Pyrazoles
  • JAK2 protein, human
  • Janus Kinase 2